Duphaston (Dydrogesterone): Pharmacology and Clinical Benefits
Pharmacology
Dydrogesterone is a potent orally active retro-progestogen that is structurally similar to endogenous progesterone but differs fundamentally from most synthetic progestogens by lacking estrogenic, androgenic, glucocorticoid, or anabolic effects 1. This unique pharmacological profile makes it highly selective in its progestogenic action.
The compound has been in clinical use for over 40 years and belongs to the class of retrosteroids 1. Unlike other synthetic progestogens, dydrogesterone demonstrates:
- Selective progestogenic activity without the metabolic side effects typical of other synthetic progestogens
- Neutral effects on the vascular system, neither causing vasoconstriction nor negatively impacting blood pressure 2
- Largely neutral effects on hemostasis and lipid metabolism, potentially intensifying rather than attenuating beneficial estrogenic effects 2
- Inhibitory effects on sulfatase and 17β-hydroxysteroid dehydrogenase (17β-HSD) activities in breast tissue, which may reduce local estradiol formation 3
Clinical Benefits and Applications
Hormone Replacement Therapy (Primary Use)
Dydrogesterone is primarily used as the progestogen component in menopausal hormone therapy for women with an intact uterus. When combined with estrogen for at least 12 days per month, dydrogesterone provides endometrial protection and reduces the risk of endometrial hyperplasia 4.
Critical safety consideration: A large observational study found that micronized progesterone and dydrogesterone, when combined with estrogen and continued beyond 5 years, were associated with an approximate 2-fold increase in endometrial cancer risk 4. However, shorter-term RCTs (2-3 years) demonstrated endometrial safety, particularly when formulated in combination tablets that enhance compliance 4.
Premature Ovarian Insufficiency
For adolescents with premature ovarian insufficiency (POI), dydrogesterone 5-10 mg/day for 12-14 days per month is the preferred progestogen option 5. This recommendation is based on its less negative effect on lipid metabolism and fewer androgenic effects compared to other progestogens 5.
Threatened Miscarriage
A systematic review of 5 randomized trials (660 women) demonstrated that dydrogesterone reduces miscarriage risk by 47% compared to standard care (13% vs 24% miscarriage rate; OR 0.47,95% CI 0.31-0.7) 6. This represents an 11% absolute reduction in miscarriage rate with minimal adverse effects 6.
Assisted Reproductive Technology (ART)
Recent evidence on dydrogesterone for luteal phase support in frozen embryo transfer (FET) cycles shows:
- Comparable ongoing pregnancy rates, clinical pregnancy rates, and live birth rates to vaginal progesterone 7
- May rescue suboptimal progesterone levels (<10 µg/L) on transfer day when administered orally from the day of embryo transfer 8
- Offers ease of administration compared to vaginal routes 7
However, preterm birth prevention data is insufficient: A 2026 meta-analysis found no statistically significant benefit over placebo, with low to very low certainty of evidence 9.
Dysmenorrhea
Dydrogesterone 20 mg/day (days 5-25) significantly reduces prostaglandin F2α levels in menstrual blood and normalizes the disturbed estradiol/progesterone ratio that contributes to dysmenorrhea 10.
Critical Safety Concerns
A 2025 disproportionality analysis of the WHO pharmacovigilance database (VigiBase) identified a concerning safety signal: Dydrogesterone showed significantly increased reporting of birth defects, particularly hypospadias and congenital heart defects, compared to any other drug (ROR 5.4,95% CI 3.9-7.5) and compared to progesterone (ROR 5.4,95% CI 3.7-7.9) 11.
This finding necessitates careful counseling when prescribing dydrogesterone during early pregnancy and warrants further investigation 11. The signal is particularly relevant for ART applications where exposure occurs during critical organogenesis periods.
Common Pitfalls to Avoid
- Do not use dydrogesterone for more than 5 years in continuous HRT without careful endometrial surveillance, given the increased endometrial cancer risk 4
- Do not assume equivalence with natural progesterone for all indications—the birth defect signal requires caution in early pregnancy 11
- Do not use in breast cancer survivors—HRT is generally contraindicated 5
- Ensure adequate duration (at least 12 days per month) when using for endometrial protection in HRT 4